News Elicio Therapeutics, Inc.

Equities

ELTX

US28657F1030

End-of-day quote Nasdaq Other stock markets 06:00:00 2024-05-14 pm EDT			5-day change	1st Jan Change
10.4 ^USD	+0.97%		+7.77%	+24.70%

Apr. 05	Elicio Therapeutics, Inc. to Present Updated Clinical T Cell and Antigen Spreading Response Data from the Ongoing Amplify-201 Phase 1 Study of ELI-002 and ElI-008 at the AACR Annual Meeting	CI
Mar. 29	Elicio Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Elicio Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Updates	May. 15	AQ
Elicio Therapeutics to Present New Preliminary Data from the Ongoing AMPLIFY-7P Phase 1/2 Study of ELI-002 7P in Patients with mKRAS-driven Solid Tumors at the 2024 ASCO Annual Meeting	Apr. 25	AQ
Elicio Therapeutics, Inc. to Present Updated Clinical T Cell and Antigen Spreading Response Data from the Ongoing Amplify-201 Phase 1 Study of ELI-002 and ElI-008 at the AACR Annual Meeting	Apr. 05	CI
Elicio Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 29	CI
Elicio Therapeutics, Inc. announced that it has received $5.999999 million in funding from Gkcc, LLC	Mar. 18	CI
Elicio Therapeutics, Inc. announced that it expects to receive $5.999999 million in funding from Gkcc, LLC	Mar. 17	CI
Elicio Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference	Feb. 05	GL
Elicio Therapeutics Announces Publication of Preclinical Data Demonstrating TCR-T Cell Therapy in Combination with Lymph Node-Targeted Amphiphile-Immunotherapy Enhanced Anti-Tumor Function and Eradicated Solid Tumors	Jan. 25	GL
Elicio Therapeutics, Inc. Announces Publication of Preclinical Data Demonstrating TCR-T Cell Therapy in Combination with Lymph Node-Targeted Amphiphile-Immunotherapy Enhanced Anti-Tumor Function and Eradicated Solid Tumors	Jan. 25	CI
Elicio Therapeutics to Present ELI-002 7P (AMPLIFY-7P) Trial in Progress Poster on Phase 1/2 Study of Lymph Node-Targeted Vaccine at ASCO GI Symposium	Jan. 17	GL
Elicio Therapeutics to Present at the B. Riley Securities 4th Annual Oncology Conference	Jan. 16	GL
Elicio Therapeutics Reports First Patient Dosed in Mid-Stage Pancreatic Cancer Trial	Jan. 11	MT
Elicio Therapeutics Announces First Patient Dosed in Randomized Phase 2 Pancreatic Cancer Study	Jan. 11	GL
Elicio Therapeutics, Inc. Announces First Patient Dosed in Randomized Phase 2 Pancreatic Cancer Study	Jan. 11	CI
Nature Medicine Publishes Updated Preliminary Phase 1 Data From Elicio Therapeutic’s AMPLIFY-201 Phase 1 Solid Tumor Study of ELI-002	Jan. 09	GL
Elicio Therapeutics, Inc. Publishes Updated Preliminary Phase 1 Data from AMPLIFY-201 Phase 1 Solid Tumor Study of ELI-002	Jan. 09	CI
Elicio Therapeutics Announces $7.0 Million Private Placement Financing	Dec. 22	GL
Elicio Therapeutics, Inc. announced that it has received $7.04753 million in funding	Dec. 21	CI
Elicio Therapeutics to Present at the H.C. Wainwright 4th Annual Precision Oncology Virtual Conference	Dec. 04	GL
Elicio Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Elicio Therapeutics, Inc.

Equities

ELTX

US28657F1030

Summary

Filters